The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia

被引:0
作者
Anneli Uusküla
Andres Müürsepp
Kosuke Kawai
Mait Raag
Mikk Jürisson
Matthew Pillsbury
机构
[1] University of Tartu,Department of Public Health
[2] Merck Sharp & Dohme OÜ,undefined
[3] Temple University,undefined
[4] East Tallinn Central Hospital,undefined
[5] Atlas Data Systems,undefined
来源
BMC Infectious Diseases | / 13卷
关键词
HPV; Vaccine; Cost effectiveness; Screening; Cervical cancer; Genital warts; Estonia;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 64 条
[1]  
Seto K(2012)The cost effectiveness of human papillomavirus vaccines: a systematic review Drugs 72 715-743
[2]  
Marra F(2010)Cost-effectiveness of 12-and 15-year-old girls' human papillomavirus 16/18 population-based vaccination programmes in Lithuania Scand J Public Health 38 639-647
[3]  
Raymakers A(2010)The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary J Med Econ 13 110-118
[4]  
Marra CA(2010)Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia Eur J Public Health 20 415-421
[5]  
Vanagas G(2012)[Economic effectiveness of vaccination against papilloma virus in the Russian Federation] Zh Mikrobiol Epidemiol Immunobiol 2 43-50
[6]  
Padaiga Z(2010)Impact of implementing a nationwide cervical cancer screening program on female population coverage by Pap-tests in Estonia Tumori 96 524-528
[7]  
Kurtinaitis J(2010)Impact of vaccinating boys and men against HPV in the United States Vaccine 28 6858-6867
[8]  
Logminiene Z(2011)Worldwide burden of cervical cancer in 2008 Ann Oncol 22 2675-2686
[9]  
Dasbach EJ(2011)HPV vaccine against anal HPV infection and anal intraepithelial neoplasia N Engl J Med 365 1576-1585
[10]  
Nagy L(2009)A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions Cancer Prev Res (Phila) 2 868-878